Do analysts prefer BGM or PLYX?

Polaryx Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 272.17%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has stronger valuation and earnings, BGM or PLYX?

Polaryx Therapeutics has lower revenue, but higher earnings than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $37.92M 0.84 -$19.94M N/A N/A Polaryx Therapeutics N/A N/A -$8.98M -$0.08 N/A

Is BGM or PLYX more profitable?

Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Polaryx Therapeutics N/A N/A N/A

Do analysts recommend PYPD or BGM?

PolyPid currently has a consensus target price of $11.33, suggesting a potential upside of 123.54%. Given PolyPid's stronger consensus rating and higher probable upside, equities research analysts plainly believe PolyPid is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PolyPid 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, PYPD or BGM?

BGM Group has higher revenue and earnings than PolyPid. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PolyPid N/A N/A -$34.17M -$1.48 N/A BGM Group $37.92M 0.84 -$19.94M N/A N/A

Is PYPD or BGM more profitable?

BGM Group's return on equity of 0.00% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -311.08% -150.83% BGM Group N/A N/A N/A

Which has preferable earnings and valuation, CGTX or BGM?

BGM Group has higher revenue and earnings than Cognition Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cognition Therapeutics N/A N/A -$23.49M -$0.17 N/A BGM Group $37.92M 0.84 -$19.94M N/A N/A

Is CGTX or BGM more profitable?

BGM Group's return on equity of 0.00% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -50.17% -40.22% BGM Group N/A N/A N/A

Do analysts rate FBIO or BGM?

Fortress Biotech currently has a consensus price target of $17.00, suggesting a potential upside of 513.72%. Given Fortress Biotech's stronger consensus rating and higher possible upside, research analysts clearly believe Fortress Biotech is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortress Biotech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, FBIO or BGM?

Fortress Biotech has higher revenue and earnings than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fortress Biotech $63.26M 1.46 $6.82M $2.64 1.05 BGM Group $37.92M 0.84 -$19.94M N/A N/A

Do analysts rate ALDX or BGM?

Aldeyra Therapeutics presently has a consensus target price of $5.50, indicating a potential upside of 270.37%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aldeyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, ALDX or BGM?

BGM Group has higher revenue and earnings than Aldeyra Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aldeyra Therapeutics N/A N/A -$33.85M -$0.39 N/A BGM Group $37.92M 0.84 -$19.94M N/A N/A

Is ALDX or BGM more profitable?

BGM Group's return on equity of 0.00% beat Aldeyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -53.14% -34.94% BGM Group N/A N/A N/A

BGM Group (BGM) Competitors

$0.33 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$0.30 -0.02 (-7.48%)

As of 04:47 AM Eastern

Compare

BGM vs. PLYX, PYPD, CGTX, FBIO, and ALDX

Should you buy BGM Group stock or one of its competitors? BGM Group's main competitors and comparable companies include Polaryx Therapeutics (PLYX), PolyPid (PYPD), Cognition Therapeutics (CGTX), Fortress Biotech (FBIO), and Aldeyra Therapeutics (ALDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does BGM Group compare to Polaryx Therapeutics?

BGM Group (NASDAQ:BGM) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Polaryx Therapeutics has lower revenue, but higher earnings than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$37.92M	0.84	-$19.94M	N/A	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A

In the previous week, Polaryx Therapeutics had 1 more articles in the media than BGM Group. MarketBeat recorded 2 mentions for Polaryx Therapeutics and 1 mentions for BGM Group. BGM Group's average media sentiment score of 1.87 beat Polaryx Therapeutics' score of 0.93 indicating that BGM Group is being referred to more favorably in the media.

Company	Overall Sentiment
BGM Group	Very Positive
Polaryx Therapeutics	Positive

Polaryx Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 272.17%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Polaryx Therapeutics	N/A	N/A	N/A

Summary

Polaryx Therapeutics beats BGM Group on 6 of the 8 factors compared between the two stocks.

How does BGM Group compare to PolyPid?

PolyPid (NASDAQ:PYPD) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

In the previous week, PolyPid had 2 more articles in the media than BGM Group. MarketBeat recorded 3 mentions for PolyPid and 1 mentions for BGM Group. BGM Group's average media sentiment score of 1.87 beat PolyPid's score of 1.57 indicating that BGM Group is being referred to more favorably in the news media.

Company	Overall Sentiment
PolyPid	Very Positive
BGM Group	Very Positive

PolyPid currently has a consensus target price of $11.33, suggesting a potential upside of 123.54%. Given PolyPid's stronger consensus rating and higher probable upside, equities research analysts plainly believe PolyPid is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BGM Group's return on equity of 0.00% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
BGM Group	N/A	N/A	N/A

PolyPid has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

BGM Group has higher revenue and earnings than PolyPid.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
BGM Group	$37.92M	0.84	-$19.94M	N/A	N/A

26.5% of PolyPid shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Comparatively, 58.7% of BGM Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

BGM Group beats PolyPid on 7 of the 12 factors compared between the two stocks.

How does BGM Group compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Cognition Therapeutics presently has a consensus target price of $3.33, suggesting a potential upside of 226.80%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cognition Therapeutics is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BGM Group has higher revenue and earnings than Cognition Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A
BGM Group	$37.92M	0.84	-$19.94M	N/A	N/A

Cognition Therapeutics has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

In the previous week, Cognition Therapeutics had 2 more articles in the media than BGM Group. MarketBeat recorded 3 mentions for Cognition Therapeutics and 1 mentions for BGM Group. BGM Group's average media sentiment score of 1.87 beat Cognition Therapeutics' score of 1.07 indicating that BGM Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Cognition Therapeutics	Positive
BGM Group	Very Positive

43.3% of Cognition Therapeutics shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by insiders. Comparatively, 58.7% of BGM Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BGM Group's return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-50.17%	-40.22%
BGM Group	N/A	N/A	N/A

Summary

BGM Group beats Cognition Therapeutics on 7 of the 12 factors compared between the two stocks.

How does BGM Group compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

Fortress Biotech has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market.

96.5% of Fortress Biotech shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by company insiders. Comparatively, 58.7% of BGM Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Fortress Biotech has a net margin of 163.32% compared to BGM Group's net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat BGM Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
BGM Group	N/A	N/A	N/A

Fortress Biotech currently has a consensus price target of $17.00, suggesting a potential upside of 513.72%. Given Fortress Biotech's stronger consensus rating and higher possible upside, research analysts clearly believe Fortress Biotech is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Fortress Biotech has higher revenue and earnings than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.46	$6.82M	$2.64	1.05
BGM Group	$37.92M	0.84	-$19.94M	N/A	N/A

In the previous week, Fortress Biotech had 2 more articles in the media than BGM Group. MarketBeat recorded 3 mentions for Fortress Biotech and 1 mentions for BGM Group. BGM Group's average media sentiment score of 1.87 beat Fortress Biotech's score of 0.85 indicating that BGM Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Fortress Biotech	Positive
BGM Group	Very Positive

Summary

Fortress Biotech beats BGM Group on 11 of the 14 factors compared between the two stocks.

How does BGM Group compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

In the previous week, Aldeyra Therapeutics had 1 more articles in the media than BGM Group. MarketBeat recorded 2 mentions for Aldeyra Therapeutics and 1 mentions for BGM Group. BGM Group's average media sentiment score of 1.87 beat Aldeyra Therapeutics' score of 1.32 indicating that BGM Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Aldeyra Therapeutics	Positive
BGM Group	Very Positive

Aldeyra Therapeutics has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market.

Aldeyra Therapeutics presently has a consensus target price of $5.50, indicating a potential upside of 270.37%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BGM Group's return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
BGM Group	N/A	N/A	N/A

BGM Group has higher revenue and earnings than Aldeyra Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A
BGM Group	$37.92M	0.84	-$19.94M	N/A	N/A

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 58.7% of BGM Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

BGM Group beats Aldeyra Therapeutics on 7 of the 12 factors compared between the two stocks.

Get BGM Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BGM vs. The Competition

Export

Metric	BGM Group	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$31.84M	$12.11B	$7.18B	$12.89B
Dividend Yield	N/A	2.62%	2.54%	11.27%
P/E Ratio	N/A	787.65	273.17	25.45
Price / Sales	0.84	759.94	638.21	103.75
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	0.08	10.49	11.08	6.36
Net Income	-$19.94M	$2.83B	$3.48B	$349.79M
7 Day Performance	30.79%	0.58%	0.38%	-0.40%
1 Month Performance	16.13%	5.69%	7.89%	4.24%
1 Year Performance	-95.64%	6.19%	24.71%	15.13%

BGM Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BGM BGM Group	1.1444 of 5 stars	$0.33 flat	N/A	-95.6%	$31.84M	$37.92M	N/A	298	Positive News Gap Down High Trading Volume
PLYX Polaryx Therapeutics	2.9279 of 5 stars	$2.04 +2.7%	$7.67 +275.1%	N/A	$101.89M	N/A	N/A	11	Gap Up
PYPD PolyPid	3.2097 of 5 stars	$5.09 -0.2%	$11.33 +122.7%	+51.3%	$99.41M	N/A	N/A	80	Short Interest Decrease
CGTX Cognition Therapeutics	2.5794 of 5 stars	$1.02 -1.5%	$3.33 +228.4%	-58.0%	$96.52M	N/A	N/A	20	Positive News
FBIO Fortress Biotech	2.5965 of 5 stars	$2.80 -1.1%	$17.00 +507.4%	+7.4%	$93.35M	$68.47M	1.06	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BGM) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BGM Group (BGM) Competitors

BGM vs. PLYX, PYPD, CGTX, FBIO, and ALDX

How does BGM Group compare to Polaryx Therapeutics?

Summary

How does BGM Group compare to PolyPid?

Summary

How does BGM Group compare to Cognition Therapeutics?

Summary

How does BGM Group compare to Fortress Biotech?

Summary

How does BGM Group compare to Aldeyra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM vs. The Competition

BGM Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BGM Group (BGM) Competitors

BGM vs. PLYX, PYPD, CGTX, FBIO, and ALDX

How does BGM Group compare to Polaryx Therapeutics?

Which has stronger valuation and earnings, BGM or PLYX?

Does the media prefer BGM or PLYX?

Do analysts prefer BGM or PLYX?

Is BGM or PLYX more profitable?

Summary

How does BGM Group compare to PolyPid?

Does the media prefer PYPD or BGM?

Do analysts recommend PYPD or BGM?

Is PYPD or BGM more profitable?

Which has more volatility and risk, PYPD or BGM?

Which has preferable earnings & valuation, PYPD or BGM?

Do institutionals & insiders have more ownership in PYPD or BGM?

Summary

How does BGM Group compare to Cognition Therapeutics?

Do analysts rate CGTX or BGM?

Which has preferable earnings and valuation, CGTX or BGM?

Which has more risk and volatility, CGTX or BGM?

Does the media refer more to CGTX or BGM?

Do insiders & institutionals have more ownership in CGTX or BGM?

Is CGTX or BGM more profitable?

Summary

How does BGM Group compare to Fortress Biotech?

Which has more risk & volatility, FBIO or BGM?

Do insiders and institutionals have more ownership in FBIO or BGM?

Is FBIO or BGM more profitable?

Do analysts rate FBIO or BGM?

Which has stronger valuation and earnings, FBIO or BGM?

Does the media prefer FBIO or BGM?

Summary

How does BGM Group compare to Aldeyra Therapeutics?

Does the media prefer ALDX or BGM?

Which has more risk and volatility, ALDX or BGM?

Do analysts rate ALDX or BGM?

Is ALDX or BGM more profitable?

Which has higher valuation and earnings, ALDX or BGM?

Do insiders & institutionals hold more shares of ALDX or BGM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM vs. The Competition

BGM Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools